Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Sales (2019 - 2025)

Historic Return on Sales for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 1.53%.

  • BridgeBio Pharma's Return on Sales rose 585900.0% to 1.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.2%, marking a year-over-year decrease of 1300.0%. This contributed to the annual value of 2.45% for FY2024, which is 677700.0% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Return on Sales is 1.53%, which was up 585900.0% from 1.66% recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Return on Sales high stood at 217.55% for Q4 2021, and its period low was 433.5% during Q3 2022.
  • Moreover, its 5-year median value for Return on Sales was 45.46% (2024), whereas its average is 70.9%.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Return on Sales was 13487200bps (2021), while the steepest drop was -4088600bps (2021).
  • BridgeBio Pharma's Return on Sales (Quarter) stood at 217.55% in 2021, then tumbled by -136bps to 77.61% in 2022, then tumbled by -42bps to 110.09% in 2023, then skyrocketed by 59bps to 45.46% in 2024, then surged by 97bps to 1.53% in 2025.
  • Its last three reported values are 1.53% in Q3 2025, 1.66% for Q2 2025, and 1.21% during Q1 2025.